Adaptive Biotechnologies
ADPT
225 hedge funds and large institutions have $1.14B invested in Adaptive Biotechnologies in 2025 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 73 increasing their positions, 68 reducing their positions, and 19 closing their positions.
105% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 19
32% more capital invested
Capital invested by funds: $859M → $1.14B (+$277M)
9% more funds holding
Funds holding: 207 → 225 (+18)
5.83% more ownership
Funds ownership: 97.09% → 102.92% (+5.8%)
7% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 68
3% more call options, than puts
Call options by funds: $383K | Put options by funds: $372K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$45.4M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$36.9M |
| 3 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$16.4M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$13.4M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$10M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$25.3M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$22.9M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$13M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$11.4M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$8.18M |
ADPT Hedge Fund Activity: Q1 2025 in Review
225 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q1 2025, worth a combined $1.14B — up 32% from $859M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new ADPT positions and 19 closed out — a net gain of 20 holders — while 73 added to existing stakes and 68 trimmed.
The largest buyer was Ameriprise, adding an estimated $45.4M. The largest seller was Millennium Management, cutting an estimated $25.3M.
- 225 institutional investors held Adaptive Biotechnologies (ADPT) as of Q1 2025, up from 207 in Q4 2024.
- Funds reported $1.14B of Adaptive Biotechnologies stock for Q1 2025, up 32% quarter-over-quarter.
- 39 funds opened new Adaptive Biotechnologies positions in Q1 2025 and 19 closed out, a net change of +20 holders.
- The largest Adaptive Biotechnologies buyer in Q1 2025 was Ameriprise, an estimated $45.4M added.
- The largest Adaptive Biotechnologies seller in Q1 2025 was Millennium Management, an estimated $25.3M sold.
Based on aggregated 13F filings for Q1 2025.